EUVIMEDEUVIMED entdecken
CrossrefInfokarte

ITGAM + Extracellular Vesicles Trigger CD8 + T Cell Activation via S100a9‐Mediated Metabolic Reprogramming in Acute Kidney Injury

Yu‐Qi Fu, Yi‐Lin Zhang, An‐Ran Shen, Ning Li, Jing Song, Yan Bao, Si‐Meng Wang, Ding‐Ding Xue, Min Wu, Bin Wang, Yi Wen, Tao‐Tao Tang, Lin‐Li Lv, Bi‐Cheng Liu

Journal of Extracellular Vesicles · 2026-11 · 15 (11)

DOI: 10.1002/jev2.70404 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Acute kidney injury (AKI) is a prevalent condition with limited therapeutic options, in which sustained renal injury driven by inflammation remains a central pathological challenge. Here, we identify a specific subset of extracellular vesicles (EVs) as the critical link translating early myeloid inflammation into metabolically fuelled CD8 + T cell pathogenicity. Using single‐EV surface proteomics via a proximity barcoding assay in a murine ischemia‐reperfusion injury model, we mapped the renal EV landscape and discovered a myeloid‐derived ITGAM + EV subset with markedly increased abundance after injury. Using a CD63‐PAGFP ITGAM‐KI reporter mouse that genetically enhances ITGAM + EV release, we further validated that these EVs interact with CD8 + T cells in the renal lymphatic niche, driving their pro‐inflammatory activation. Proteomic profiling pinpointed S100a9 as the functional cargo on these ITGAM + EVs. Mechanistically, EV‐delivered S100a9 stabilized the mitochondrial aspartate‐glutamate carrier Slc25a12 in recipient CD8 + T cells, thereby enhancing glutamate metabolism to fuel a pathogenic transcriptional program. Pharmacological inhibition of S100a9 with tasquinimod, combined with genetic loss of S100a9 in bone marrow‐derived myeloid cells, established the necessity of EV‐associated S100a9 in driving CD8 + T cell activation. Our findings establish ITGAM + EVs as essential mediators of pro‐metabolic and pro‐inflammatory signal in AKI and highlight the S100a9–Slc25a12 axis as a promising therapeutic target for intercepting sterile inflammation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →